Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Ophthalmology. 2014 Jan;121(1):334-341. doi: 10.1016/j.ophtha.2013.09.004. Epub 2013 Oct 18.
To describe the clinical features, ancillary diagnostic studies, and treatment selection in a cohort of patients with uveal lymphoma.
Retrospective clinical review.
A total of 22 patients (34 affected eyes) diagnosed with uveal lymphoma between 1997 and 2013.
Data were collected regarding patient characteristics, clinical features on ophthalmic examination, ancillary imaging studies, and primary treatment selection.
Relapse defined as lymphoma recurrence in the initial site of presentation, the contralateral eye, or other systemic site and overall survival.
Fifteen patients were male (68.2%). Median age at diagnosis was 68.0 years. The choroid was involved in 21 cases (95.5%), and 1 case (4.5%) was ciliochoroidal. Other ocular adnexal structures were affected in 13 patients (59.1%), including the conjunctiva in 4 (18.2%), the orbit in 7 (31.8%), and both the conjunctiva and orbit in 2 (9.1%). Bilateral disease was present in 12 patients (54.5%). The most common presenting symptom was decreased vision in 15 patients (68.2%). The median delay in diagnosis was 4.0 months. Yellow-white choroidal infiltrates were observed on fundus examination in 34 eyes (100.0%) with corresponding hypofluorescence in 100% of cases when indocyanine green angiography was performed. Infiltrates were located anterior to the arcades (67.6%), most commonly in a diffuse (32.4%) or superotemporal (32.4%) distribution. B-scan ultrasonography detected extrascleral extension in 22 patients (75.9%) with a pattern of crescentic thickening in 19 (86.4%). Extranodal marginal zone lymphoma was the predominant (76.2%) histologic subtype. External beam radiotherapy (72.7%) was most commonly chosen for primary treatment. Systemic imaging at the time of diagnosis revealed that the majority of cases (77.3%) were localized to the eye; none of the patients developed new systemic disease (median follow-up, 30.3 months).
Uveal lymphoma has distinctive clinical features. Overlap with ocular adnexal structures is common, and ancillary imaging is essential for evaluating the full extent of ocular disease and presence of systemic involvement.
描述一组葡萄膜淋巴瘤患者的临床特征、辅助诊断研究和治疗选择。
回顾性临床研究。
共 22 例(34 只受累眼)患者,均于 1997 年至 2013 年间被诊断为葡萄膜淋巴瘤。
收集患者特征、眼部检查的临床特征、辅助成像研究和主要治疗选择的数据。
复发定义为初始部位、对侧眼或其他全身部位的淋巴瘤复发以及总生存。
15 例为男性(68.2%)。诊断时的中位年龄为 68.0 岁。21 例(95.5%)累及脉络膜,1 例(4.5%)累及睫状体脉络膜。13 例(59.1%)其他眼部附属结构受累,其中 4 例(18.2%)累及结膜,7 例(31.8%)累及眼眶,2 例(9.1%)同时累及结膜和眼眶。12 例(54.5%)为双侧疾病。最常见的首发症状为 15 例(68.2%)视力下降。中位诊断延迟时间为 4.0 个月。眼底检查发现 34 只眼(100.0%)有黄白色脉络膜浸润,相应的吲哚青绿血管造影检查 100%显示为弱荧光。浸润位于弓状线之前(67.6%),最常见的分布为弥漫性(32.4%)或上颞部(32.4%)。B 型超声扫描检测到 22 例(75.9%)眼球外延伸,19 例(86.4%)呈新月形增厚。结外边缘区淋巴瘤是最主要的(76.2%)组织学亚型。72.7%(16/22)的患者首选外照射放疗作为初始治疗。诊断时的全身影像学检查显示,大多数病例(77.3%)局限于眼部;无一例患者发生新的全身疾病(中位随访 30.3 个月)。
葡萄膜淋巴瘤具有独特的临床特征。与眼部附属结构的重叠很常见,辅助成像对于评估眼部疾病的全面范围和全身受累情况至关重要。